Related Experiment Video
Updated: May 23, 2025

Author Spotlight: A Novel Setup to Conduct Naturalistic Laboratory Experiments with Real Human Actors in Scenarios
Published on: August 4, 2023
AKT1E17K-Interacting lncRNA SVIL-AS1 Promotes AKT1 Oncogenic Functions by Preferentially Blocking AKT1E17K
Jingyi Wang1, Wenying Chen2, Qianying Li1
1Department of Otolaryngology-Head and Neck Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
Abstract:
AKT1E17K is a gain-of-function mutation that constitutively activates the PI3K-AKT pathway. However, how AKT1E17K is regulated in cancer pathogenesis remains elusive. Here, RNA immunoprecipitation sequencing (RIP-seq) is performed to interrogate the AKT1E17K-interacting lncRNAs and identify that SVIL-AS1 preferentially binds to AKT1E17K rather than AKT1WT proteins. It is found that SVIL-AS1 enhances AKT1 phosphorylation and downstream signaling. SVIL-AS1 knockdown dramatically inhibits the growth of AKT1E17K cells in vitro and in vivo. Notably, AKT1 and SVIL-AS1 interaction is AKT1 phosphorylation-dependent. SVIL-AS1 also interacts with PPP2R2A, a subunit of phosphatase PP2A holoenzyme, and blocks the binding of PPP2R2A to AKT1E17K to prevent AKT1 dephosphorylation. Moreover, AKT1E17K cells are not effectively inhibited by the allosteric AKT inhibitor, whereas silencing SVIL-AS1 sensitizes AKT1E17K cells to AKT1 allosteric inhibitor, as well as the PI3Kα inhibitor. In breast cancer tissues, SVIL-AS1 is highly expressed and associated with p-AKT1 level and poor prognosis of patients. Together, the findings discover a novel lncRNA regulator of mutant oncoprotein which preferentially prevents AKT1E17K dephosphorylation. Targeting SVIL-AS1 may help to improve the responses to inhibitors of the PI3K-AKT pathway, especially in AKT1E17K mutant tumors.
Insights
Researchers discovered a novel long non-coding RNA, SVIL-AS1, that stabilizes the cancer-driving AKT1E17K mutation by preventing its dephosphorylation. Targeting SVIL-AS1 may improve treatments for AKT1E17K-mutant cancers.
Area of Science:
- Molecular Oncology
- Cancer Biology
- RNA Biology
Background:
- The PI3K-AKT pathway is crucial in cancer, often activated by mutations like AKT1E17K.
- Understanding the regulation of mutant AKT1 is vital for developing targeted therapies.
- The role of long non-coding RNAs (lncRNAs) in regulating oncogenic proteins is an emerging area.
Purpose of the Study:
- To identify lncRNAs that interact with and regulate the AKT1E17K oncoprotein.
- To elucidate the mechanism by which SVIL-AS1 affects AKT1E17K activity and cancer cell growth.
- To evaluate the therapeutic potential of targeting SVIL-AS1 in AKT1E17K-mutant cancers.
Main Methods:
- RNA immunoprecipitation sequencing (RIP-seq) to identify AKT1E17K-interacting lncRNAs.
- In vitro and in vivo experiments to assess the functional role of SVIL-AS1 in AKT1E17K cells.
- Co-immunoprecipitation and phosphatase assays to investigate the interaction between SVIL-AS1, AKT1, and PPP2R2A.
- Analysis of breast cancer patient tissues to correlate SVIL-AS1 expression with clinical outcomes.
Main Results:
- SVIL-AS1 was identified as a lncRNA that preferentially binds to AKT1E17K over wild-type AKT1.
- SVIL-AS1 enhances AKT1E17K phosphorylation and downstream signaling, promoting cancer cell growth.
- SVIL-AS1 inhibits AKT1E17K dephosphorylation by blocking the interaction between AKT1E17K and the phosphatase PPP2R2A.
- Silencing SVIL-AS1 sensitizes AKT1E17K cells to AKT1 and PI3K inhibitors and is associated with poor prognosis in breast cancer.
Conclusions:
- SVIL-AS1 acts as a novel lncRNA regulator that stabilizes the AKT1E17K oncoprotein.
- SVIL-AS1 prevents AKT1E17K dephosphorylation through interaction with PPP2R2A.
- Targeting SVIL-AS1 offers a potential strategy to enhance the efficacy of PI3K-AKT pathway inhibitors in AKT1E17K-mutant tumors.
Related Concept Videos
Introduction to Actin
Actin Treadmilling
Formation of Higher-order Actin Filaments
The high-order actin...
Actin Filament Depolymerization
In F-actin, the ADF/cofilin proteins...
Actin Polymerization
The nucleation phase involves forming a stable nucleus consisting of three actin monomers to form a new actin filament. Actin-binding proteins such as formins and Arp2/3 complex help filament growth post-nucleation. The Formins form straight...
The Role of Actin and Myosin in Non-muscle Cells

